Movement Alert｜GENSCRIPT B-1K Intraday Rise 3.3% in Regular Trading, Backed by Continued Institutional Buying and CARVYKTI Sales Update

Market Focus10-20

On October 20, GENSCRIPT B-1K recorded an Intraday Rise of 3.3% in Regular Trading, trading at HK$34.56 with turnover of HK$322 million.

The most recent publicly available catalyst points to continued institutional accumulation. A recent disclosure showed FMR LLC bought 10.37 million shares on October 12 at an average price of HK$42.059 per share, involving about HK$436 million and lifting its stake to 7.26%.

This followed earlier purchases by FMR LLC on September 24 and October 2, reinforcing the signal of sustained external fund interest. Separately, the company disclosed that associate Legend Biotech's core product CARVYKTI generated about US$710 million in net trade sales for the quarter ended September 30, supporting attention on the company’s cell therapy exposure alongside its life sciences tools and services business.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment